alkylguanine-DNA alkyltransferase (AGT), encoded by the methylguanine methyltransferase gene [MGMT] , removes the methyl group thereby preventing the mutation from occurring. When overexpressed in the thymus, MGMT protects mice from MNU-induced thymic lymphomas. To determine whether MGMT overexpression reduced G : C to A : T mutation frequency after MNU, Big Blue TM lacI and MGMT+/Big Blue TM mice were treated with MNU and analysed for mutations in the lacI and K-ras genes. The incidence of MNUinduced lymphomas was 84% in Big Blue TM lacI mice compared to 14% in MGMT+Big Blue TM lacI mice. Sixty-two per cent of the lymphomas had a GGT to GAT activating mutation in codon 12 of K-ras consistent with O 6 mG adduct-mediated point mutagenesis. LacI mutation frequency in thymus of MNU treated Big Blue TM mice was 45-fold above background whereas it was 11-fold above background in MNU treated MGMT+/Big Blue TM mice. Most lacI mutations were G : C to A : T transitions, implicating O 6 mG even in the MGMT+ mice. No mutations were attributable to chromosomal aberrations or rearrangements. Thus, O 6 mG adducts account for the carcinogenic eect of MNU and MGMT overexpression is selectively able to reduce O 6 methylguanine adducts below a carcinogenic threshold. Other adducts are mutagenic but appear to contribute much less to malignant transformation or oncogene activation.
Keywords: Big Blue lacI mice; mutation frequency; hMGMT mice; N-methyl-N-nitrosourea induced lymphoma O 6 methylguanine (O 6 mG) adducts are a major component of the mutagenesis and carcinogenesis induced by methylating agents such as MNU. Unrepaired O 6 mG adducts aberrantly base pair with thymine during replication resulting in G : C to A : T point mutations after subsequent rounds of DNA replication (Domoradzki, et al., 1985) . Likewise, MNU induces chromosomal aberrations and sister chromatid exchanges in mismatch repair competent cells (Trey and Gerson, 1989; Galloway et al., 1995) . The DNA repair protein AGT, encoded by the MGMT gene, eciently repairs O 6 mG adducts by covalently transferring the methyl group from the O 6 position of guanine to a cysteine residue within its active site (Gerson et al., 1985) . This methyl transfer results in irreversible inactivation of the AGT. Thus, one AGT molecule repairs a single O 6 mG adduct.
We have previously described transgenic mice which overexpress human [h]AGT (Dumenco et al., 1993) . These mice express hAGT mainly in thymus and spleen, because the transgene contains the 2 kb locus control region from the CD2 gene. They also express hAGT in brain and kidney, but not liver. The thymus of hMGMT+ mice has 50-fold higher AGT activity and after MNU, has rapid removal of O 6 mG DNA adducts resulting in a 20-fold reduction in the level of persistent adducts compared to nontransgenic littermates (Liu et al., 1994) . Following a single i.p. injection of 80 mg/kg MNU, the incidence of thymic lymphomas in nontransgenic mice was 84% compared to 13% in hMGMT+ mice (Dumenco et al., 1993) . Since our report, others have shown a protective eect of AGT on dimethylnitrosamine induced hepatic tumors (Nakatsuru et al., 1993) and on skin tumors induced by TPA and MNU (Becker et al., 1996) . We have also shown a reduction in aberrant crypt foci in the colon of hMGMT+ mice after axoxymethane (Zaidi et al., 1995b) . These data provide direct evidence that AGT blocks MNU-induced carcinogenesis by removal of the O 6 mG adduct. None of these studies, however, have evaluated the extent to which AGT overexpression reduces MNU induced G : C to A : T mutations or the relative mutagenic eect of other MNU induced lesions. These lesions include O 2 methylthymine (O 2 mT) or O 4 mT adducts which cause T : A to C : G transitions and N 7 mG and N 3 mA adducts which are released by the methylpurine glycosylase resulting in mutagenic abasic sites (Strauss, 1991) . In the MGMT transgenic mouse models it is also unclear whether the level of DNA repair which protects against carcinogenesis requires complete removal of premutagenic O 6 mG adducts and a reduction of mutations to baseline frequency or whether there is a threshold in the level and type of mutations required for malignant transformation.
MNU is carcinogenic through its ability to induce mutational activation of an oncogene or inactivation of a suppressor gene. Previously, MNU has been shown to induce G : C to A : T mutations in N-ras codon 61 in rat mammary tumors (Zarbl et al., 1985; Cha et al., 1994) and in K-ras codon 12 (GGT) in mouse lymphomas (Corominas et al., 1991) . Thus, in mice, there should be a correlation between the number and type of mutations induced by MNU and activation of K-ras in the resulting lymphomas.
In order to establish the role of AGT in MNUinduced mutation frequencies, mice transgenic for the hMGMT were bred to Big Blue TM mice and ospring were analysed for MGMT expression. As seen in Table  1 (Dumenco et al., 1993) .
To study MGMT+/Big Blue TM mice, it was necessary to determine whether the presence of the 40 copy transgenic insert of lacI and lambda sequences in Big Blue TM mice altered susceptibility to MNU-induced lymphomas. Littermate MGMT+/Big Blue TM and Big Blue TM mice, were compared to littermate B6/SJL MGMT+ and B6/SJL mice after injection with 80 mg/kg MNU ip at 6 weeks of age. There was a similar incidence of MNU-induced thymic lymphomas in the non-MGMT ospring from the two strains of mice (83% (5/6) in Big Blue TM vs 84% in B6/SJL), Figure 1 . On the other hand, hMGMT+ mice from both crosses were markedly protected from development of lymphomas by MNU (0% in eight Big Blue TM hMGMT+ and 14% in 22 B6/SJL MGMT+ mice).
K-ras mutations in codon 12 were analysed in thymus and spleen in all MNU treated mice developing lymphomas, and in all surviving mice at 1 year. Table 2 shows that a G : C to A : T mutation in the second position of codon 12 (GGT to GAT) was present in 43 out of 59 lymphomas from mice lacking the hMGMT transgene; 38% of lymphomas from mice treated with 50 mg/kg MNU, 53% from mice treated at 80 mg/kg MNU and 69% from mice treated with The alkyltransferase assay has been published in detail (Liu et al., 1994) . Brie¯y, activity was measured in sonicated tissue extracts by quantifying the amount of [ (Dumenco et al., 1993) were bred to heterozygous male Big Blue TM (lacI+/B6; Stratagene, La Jolla, CA, USA), (Kohler et al., 1991) mice. Ospring were treated with 80 mg/kg MNU at 6 weeks of age and followed for 1 year. Mice developing signs of thoracic obstruction or weight loss were sacri®ced and autopsied. All such mice had thymic lymphomas. Left, cohort of hMGMT+ and nontransgenic mice, taken from Dumenco et al. (1993) ; Right, six Big Blue TM and eight Big Blue TM hMGMT+ mice (14) 16 (88) 6 (25) 5 (38%) ± 16 (53) 1 (33) 22 (69) 3 (50) Mutations in codon 12 at K-ras were determined as previously described (Zaidi et al., 1995b) , by restriction fragment length polymorphism (RFLP) using nested primers which insert a restriction site sequence into either mutant GAT or wild type GGT codon 12. Polymerase chain reaction (PCR) followed by restriction enzyme digestion identi®ed mutations as either G to A or not G to A. These were con®rmed at least twice and were sequenced to con®rm the mutation 30 mg/kg MNU weekly for 5 weeks. In contrast, among the nine lymphomas observed in 74 MGMT+ mice, four had codon 12 K-ras mutations. Of interest, the PCR band indicating the presence of the mutant Kras allele had low intensity in these four MGMT+ lymphomas, three of which occurred in mice treated with ®ve weekly doses of 30 mg/kg MNU. This suggests that only a sub-population of cells carried the K-ras mutation, even though the morphology was homogeneous, suggesting that the mutation may have arisen as an oligoclonal process during the last few MNU treatments, after the initial cell transformation occurred. Importantly, none of 65 MNU treated MGMT+ mice sacri®ced at 1 year had a K-ras mutation in the normal appearing thymus or spleen by RFLP ± PCR. Thymus, spleen and liver were harvested from six hMGMT+/Big Blue and seven Big Blue mice 6 days after treatment with a single dose of 80 mg/kg MNU and analysed for MNU induced mutation frequencies. Mutation frequencies represent (a) pooled data from the six Big Blue TM /hMGMT+ and seven Big Blue TM mice and expressed as a mutation frequency per cohort by tissue (mutations/PFU, strati®ed by tissue) (Table  3) , and (b) the mean mutation frequency per mouse by tissue (mutations per mouse/PFU per mouse) ( Figure  2 ), measured in each of the three tissues for the two mouse cohorts. Background mutation frequency was very similar to that previously reported (Kohler et al., 1991; de Boer et al., 1998) . MNU is a very powerful mutagen, increasing the mutation frequency 32-fold over background in the thymus and 13-fold in the spleen of Big Blue TM mice. In MNU-treated MGMT+/ Big Blue TM mice, the mutation frequency in thymus was reduced threefold (P50.01) but was still increased 12-fold above background whereas in the spleen, the mutation frequency was reduced 2.6-fold (P50.01) but remained ®vefold above background. Data analysed on the basis of total PFU are con®rmed in the analysis of mutation frequency per mouse. Less induction of mutations and no protective eect of hMGMT was seen in the liver, because of high endogenous levels of AGT and lack of hMGMT transgene expression. If lesions persisted they would have been converted to mutations in lacI during transformation into E. coli, but his was not observed.
Twenty-eight LacI mutant clones derived from Big Blue TM thymuses and 18 clones from the six hMGMT+/Big Blue TM thymuses were selected at random and isolated from lambda phage containing thymus derived DNA for sequencing. We used an equal number of isolates from each mouse to avoid identical mutations arising from cell proliferation prior to isolation. The majority of mutations in both groups were base substitutions, which accounted for 96 and 89% of all mutations in hMGMT+/Big Blue TM and Big Blue TM mice, respectively. In Big Blue TM mice, most mutations were transitions, 25/28 (89%), (Table 4) with the vast majority being G : C to A : T (23/28 or 82% of all mutations). Transversions accounted for two mutations (8%) and there was one insertion. There were ®ve mutation sites shared by two separate animals (lacI sites 183, 222, 843, 856, 888) . In hMGMT+/Big Blue TM thymus 11 of the 18 mutations (61%) were transitions, all G : C to A : T. Five mutations (28%) were transversions, with two C : G to A : T mutations. Two other mutations were insertions. Two mutations in regions with identical 6 bp sequences were identi®ed at sites 329 and 882 of lacI.
Analysis of the type-speci®c mutation frequency in the thymus provided important information of the Mutation frequency is recorded as mutants per PFU for each tissue in each cohort. Fold induction is recorded as the ratio of mutation frequencies in the MNU-treated cohort compared to the untreated cohort. Thymus, spleen and liver harvested from six hMGMT+/Big Blue and seven hMGMT+/Big Blue mice were¯ash frozen in liquid nitrogen, homogenized in douncing buer (12 nM Na 2 HPO 4 , 134 nM NaCl, 3 mM Kcl, 1 mM KH 2 PO 4 , 10 mM EDTA, pH 7.5) and subsequently digested in 2 mg/ml proteinase K (Boehringer Mannheim, Indianapolis, IN, USA) solution (2% SDS, 100 mM EDTA, pH 7.5). DNA was puri®ed by a series of phenol : chloroform extractions, precipitated in 100% ethanol and resuspended in 50 ± 500 ml 10 mM Tris, 0.1 mM EDTA, pH 8.0. 4 ± 8 mg genomic DNA was incubated 2690 min with Transpack packaging extract (Statagene, La Jolla, CA, USA) at 308C. Packaged phage were used to infect E. coli strain SCS-8 (Stratagene, La Jolla, CA, USA) and were plated (10 ± 12610 3 pfu/plate) in top agar containing 2 mg 5-bromo-4-chloro-indoyl b-galactosidase (X-gal; Stratagene, La Jolla, CA, USA). Plaques containing mutations within the lacI target (lacI, lacI promoter or operator) that prevented binding of the lacI protein to the operator region were visualized as blue plaques and con®rmed at low density mT, and targets for repair by AGT, fell 3.5-fold but remained 7 ± 8-fold above the spontaneous rate, not dissimilar to the rate of transversions and insertions.
This study provides de®nitive evidence that O 6 mG is the lesion responsible for MNU lymphomagenesis in the mouse and establishes the nature of the protective eect of hMGMT transgene mediated overexpression of AGT. The G : C to A : T transition mutation, due to mispairing with the O 6 mG adduct, was the most common mutation observed in the lacI gene of the thymus after MNU treatment in both cohorts of mice. Transition mutations were induced over 30-fold after MNU in Big Blue TM mice and reduced by a factor of 3.5 in mice expressing hMGMT, leaving a residual 7 ± 8-fold increase in transition mutations in the hMGMT+ mice after MNU. This level of mutations was only slightly higher than the combined induction of transversions and insertions induced by MNU in both cohorts of mice (4 ± 5-fold), which were not aected by MGMT transgene expression. Despite this net increase in mutations (12-fold), the hMGMT+ mice had a reduced incidence of lymphomas after 80 mg/kg MNU, from 84 to 14%.
Sixty-two per cent of the MNU-induced lymphomas had a K-ras mutation in codon 12 (GGT to GAT) which can be viewed as the signature mutation of MNU. While this mutation was expected for the mice without the MGMT transgene, this mutation was also observed in the lymphomas of hMGMT+ transgenic mice which received 30 mg/kg MNU weekly65. It is of interest in the latter mice that there was only a weak mutant PCR band suggesting that the mutant K-ras allele may have arisen in only a sub-population of malignant MGMT+ cells, perhaps after one of the later MNU doses. In contrast, PCR evidence of K-ras mutations in only a sub-population of cells was not observed in non MGMT+ mice, suggesting that it always occurred early in the carcinogenic process. The high level of G : C to A : T transition mutations detected in the lacI gene within the thymus of MNU treated hMGMT+ mice is surprising given the marked reduction in lymphomas in these mice. In the thymus of hMGMT+ mice, we have noted that over 90% of O 6 mG DNA adducts formed in the thymus are removed within 4 h whereas over 50% of these adducts remain for 48 h in nontransgenic mice (Liu et al., 1994) and we have shown that the cortical thymocyte expresses high MGMT (Zaidi et al., 1995a) . Since the G : C to A : T mutation is due to DNA replication past the O 6 mG lesion, with insertion of a T rather than a C (Moriwaki et al., 1991) , the explanation for the observed mutations in MGMT+ mice is most likely the rapid rate of cell proliferation in the thymus at 6 weeks of age, with mutations occurring within 4 ± 6 h.
By the same analysis, the level of residual transition mutations is also much higher in the spleen than we anticipated given the rapid removal of O 6 mG DNA adducts in this organ as well (Liu et al., 1994) . However, since expression of the MGMT+ transgene is higher in T than B-lymphocytes (Zaidi et al., 1995a) , the overall mutation frequency probably re¯ects a reduction in O 6 mG DNA adducts in the T but not the B-lymphocyte. It is thus remarkable that in this model, most of the lymphomas are T-cell and not B-cell in origin. From this, we conclude that the thymus is permissive for malignant transformation after MNU perhaps due to the rate of cell proliferation and other unidenti®ed facilitating oncogenic factors.
The site-speci®c analysis of mutations in Big Blue system was particularly informative. (Dosanjh et al., 1993) which are poorly repaired by hAGT (Sassanfar et al., 1991) , perhaps suggesting that hAGT overexpression did not prevent these lesions from becoming sites of Table 3 ). One hundred ml puri®ed phage stock was incubated for 15 min at 378C with E. coli strain XL-1 Blue and ExAssist helper phage (Stratagene, La Jolla, CA, USA), M13 proteins produced by the helper phage allow for positive strand synthesis of the lambda LIZ vector packaged into the lambda phage. The new strand is circularized, packaged as an M13 phage and secreted into the supernatant. This rescued M13 phage was used to infect E. coli strain SOLR cells (Stratagene, La Jolla, CA, USA) on LB containing 50 mg/ml ampicillin. Regions of lacI identi®ed as containing a mutation were sequenced using the appropriate 32 Pend labeled primer (Stratagene, La Jolla, CA, USA) using the fmol DNA sequencing system (Promega, Madison, WI, USA). Mutants not identi®ed by SSCP analysis were sequenced using a series of lacI-speci®c primers until the mutation was found Decreased mutation frequency in hMGMT transgenic mice E Allay et al mutagenic damage. A similar frequency ( 8610 75 ) of transversion or insertion mutations occurred in hMGMT+ and nontransgenic mice after MNU. The transversions may occur due to insertion opposite abasic sites which have been shown to depend on both the base excision repair and nucleotide excision repair systems (Strauss, 1991; Nivard et al., 1996) . Since the incidence of lymphomas is so much lower in hMGMT+ mice, we conclude that these particular mutations, and the residual levels of G : C to A : T mutations induced by O 6 mG, contributed little to carcinogenesis in the thymus. On the other hand, O 6 mG can induce chromosomal aberrations, rearrangements and deletions, and these are not well identi®ed by the lacI target, so that their contribution to the overall lymphomagenesis process, which would be aected by O 6 mG repair, cannot be assessed. Finally, it is possible that the lacI gene target does not re¯ect the mutation frequency or spectrum which occurs throughout the genome. Since, others have found a similar mutation spectrum after methylating agent exposure in actively transcribed genes such as hprt with preferential O 6 mG adduct repair on the transcribed strand (Lukash et al., 1991; Dobo et al., 1998) to that which we observed, and plasmid shuttle vector mutation analysis has also yielded similar mutation type changes to those observed here in the presence and absence of AGT (Moriwaki et al., 1991) , we conclude that our ®ndings are representative of the impact of AGT on mutation frequency after MNU. This is further supported by the recent ®nding that nuclear localized AGT was present in transcriptionally active regions (Ali et al., 1998) , perhaps coupled to nucleotide excision repair (Sitaram et al., 1997) . While it is likely that the overall repair of O 6 mG adducts is lower in the inactive lacI gene than in actively transcribed genes, the mutation spectrum and type speci®c frequency dierences between the Big Blue TM and MGMT+/Big Blue TM mice are also likely to be predictive of the changes found in actively transcribed genes.
Taken together, our data that a lower incidence and longer latency of lymphomas occurs in hMGMT+ mice after MNU coupled with the ®nding of a lower mutation frequency suggests that the carcinogenic process involves multiple genomic hits and therefore a mutational threshold eect of both mutation frequency and type. The G : C to A : T transition mutation appears to be more carcinogenic than transversion mutations at least in part due to K-ras codon 12 activating mutations. The transition mutations most likely also activate other cooperating genes and perhaps induce suppressor gene dysfunction in the transformation process. Other mutagenic lesions induced by MNU but not repaired by AGT (transversions which occur equally in hMGMT+ and normal mice) do not appear to contribute signi®cantly to the carcinogenic process.
Abbreviations AGT, O 6 -alkylguanine DNA-alkyltransferase protein; MGMT, methylguanine DNA-methyltransferase gene; MMR, mismatch repair; MNU, N-methyl-N-nitrosourea, PFU, plaque forming unit.
